{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-055056","form_type":"8-K","ticker":"LNSR","cik":"0001320350","company_name":"LENSAR, Inc.","filed_at":"2021-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.021057+00:00","generated_at":"2026-06-28T11:19:24.541941+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LENSAR Q3 2021 revenue $8.3M (+16% YoY), net loss widens to $6.2M","bullets":["Revenue $8.3M, up 16% YoY; procedure volumes grew 23% over Q3 2020.","Net loss of $6.2M ($0.65 loss per share) vs. $4.8M loss ($0.64 per share) in Q3 2020.","R&D spending surged 59% to $3.2M, driven by development of ALLY Adaptive Cataract Treatment System.","Cash and equivalents $32.3M; cash utilization $2.2M in the quarter.","Adjusted EBITDA was ($3.9M) compared to ($0.4M) in Q3 2020, reflecting higher R&D and SG&A."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-055056","json":"https://secwatch.observer/filing/0001564590-21-055056.json","markdown":"https://secwatch.observer/filing/0001564590-21-055056.md","text":"https://secwatch.observer/filing/0001564590-21-055056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320350/000156459021055056/0001564590-21-055056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320350/000156459021055056/lnsr-8k_20211108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:19:24.541941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}